C

Cardiology Partners Clinical Research Institute | Wellington Office

Research site
(Unclaimed)
Location
3347 State Road 7, Suite 203, Wellington, Florida, United States of America

Site insights

Top conditions

Top treatments

sodium
Milvexian
valsartan
Obicetrapib
Sacubitril
Inclisiran
Apixaban

Parent organization

This site is a part of Cardiology Partners Clinical Research Institute

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 7 total trials
Locations recently updated

A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

This is a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerabilit...

Enrolling
Heart Failure
Biological: XXB750 High Dose
Drug: Sacubitril/valsartan

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Placebo in 1.5ml
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Other: Placebo
Drug: Milvexian

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Placebo
Drug: Apixaban Placebo

The purpose of this 20-week randomized double-blind study in patients with resistant hypertension (rHTN) is to evaluate the efficacy, safety, and tol...

Active, not recruiting
Resistant Hypertension
Other: Placebo
Biological: Experimental drug

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo
Locations recently updated

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Trial sponsors

Novartis logo
J
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems